IP Library Granted Patent US 8,936,785
Granted Patent B2
US 8,936,785 · App. 12/307,875 · Granted Jan 20, 2015

scFv antibodies which pass epithelial and/or endothelial layers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,936,785
App. No.
12/307,875
Granted
Jan 20, 2015
Kind
B2
Abstract

scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with CDRs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scFv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scFV that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scFv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody.

Claims (3)

1. A composition formulated for topical application to an eye, said composition comprising an antigen-binding polypeptide and a pharmaceutically acceptable carrier, diluent, or excipient, wherein said polypeptide is sufficiently soluble such that it can transit at least one epithelial layer of the eye and into an intraocular space of the eye to achieve an intraocular therapeutic concentration in the absence of a penetration enhancer, wherein the antigen-binding polypeptide comprises the sequence of SEQ ID NO: 13, and wherein the composition has a pH of 6.5.

2. The composition of claim 1 , wherein the at least one epithelial layer is an epithelial layer of a cornea.

3. The composition of claim 1 , wherein the composition is in the form of eye drops.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2019
From: ESBATECH, A NOVARTIS COMPANY LLC
To: NOVARTIS AG
Reel/Frame 050969/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018
From: ESBATECH, A NOVARTIS COMPANY LLC
To: NOVARTIS AG
Reel/Frame 047768/0304 →
CORRECTIVE ASSIGNMENT TO CORRECT THE LEGAL STATUS OF THE ASSIGNEE AS LLC, NOT GMBH PREVIOUSLY RECORDED ON REEL 023639 FRAME 0314. ASSIGNOR(S) HEREBY CONFIRMS THE LEGAL STATUS OF THE ASSIGNEE IS ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC. Recorded Jan 4, 2010
From: ESBATECH AG
To: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC
Reel/Frame 023720/0976 →
CHANGE OF NAME Recorded Dec 11, 2009
From: ESBATECH AG
To: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT GMBH
Reel/Frame 023639/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2009
From: AUF DER MAUR, ADRIAN; BARBERIS, ALCIDE; URECH, DAVID M; LICHTLEN, PETER
To: ESBATECH AG
Reel/Frame 022987/0889 →